In a recent study using a training and confirmation cohort, four existing clinical tests available for the diagnosis of ovarian cancer (RMI score and ROMA, CA125 and HE4) and a panel of 28 immunosoluble biomarkers from 66 patients undergoing surgery for suspected ovarian cancer were assessed through a multiplex immunoassay. Here, WFDC2 is linked to ovarian cancer.